Global Pharmaceutical Excipients Market Set To Grow To $8.5bn By 2022

06 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Pharmaceutical Excipients Market Forecast to 2027 : Plant-Based, Animal Chemistry, Mineral, Synthetic, Oral Application, Topical Application, Parental Application, Other Application, Binders, Diluents, Glidants, Disintegrant, Others

The pharmaceutical industry is facing various challenges such as patent cliff, strict regulations and reduced healthcare spending; all these factors are hindering the development of new drugs. Novel excipients offer several opportunities to overcome these challenges. Novel excipients can be used to reformulate approved drugs and also improve the quality and safety of the drugs as well as reducing manufacturing cost. Manufacturers of generic drugs are now mainly focusing on reformulating and reintroducing their products with a cost-effective process to develop super generic drugs and to extent patents. Hence, various important steps are taken by key players such as modification in design and dosage forms, increasing focus on quality by design, and use of excipients in reformulation of drugs.
The lead analyst of the report commented “Pharmaceutical industry is highly dependent on the development and discovery of new molecules for the replacement of old drugs revenue stream that are going towards patent expiry. Therefore, drug formulators and innovators are mainly focusing on developing new chemical entities. Similarly, narrow pipeline of new chemical excipients, increasing preference of manufacturers for the direct compression (DC) process and technological advancement in tablets manufacturing, are some of the other factors that will give opportunity for the development of high-functionality excipients.”

Leading companies featured in the report include Evonik Industries AG, BASF SE, Innophos Holdings Inc., The Lubrizol Corporation, The DOW Chemical Company, Wacker Chemie AG, Ashland Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever